S. Moragón

Immunological Landscape of HER-2 Positive Breast Cancer

A. Lluch, B. Bermejo, J. Cejalvo, 2022, Cancers.

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

A. Lluch, P. Eroles, A. Adam-Artigues, 2021, International journal of molecular sciences.

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

F. Rojo, J. Albanell, A. Lluch, 2022, Science advances.

Fertility and breast cancer: a literature review of counseling, preservation options and outcomes.

I. Chirivella, A. Lluch, B. Bermejo, 2021, Critical reviews in oncology/hematology.

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

A. Lluch, P. Eroles, V. Constâncio, 2021, ESMO open.

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation

A. Cervantes, A. Insa, J. Martínez-Jabaloyas, 2021, ESMO Open.

Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme

B. Bermejo, A. Insa, J. Martínez-Jabaloyas, 2022, Cancer control : journal of the Moffitt Cancer Center.